Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) FCF Margin (2016 - 2025)

Ultragenyx Pharmaceutical has reported FCF Margin over the past 10 years, most recently at 48.13% for Q4 2025.

  • Quarterly FCF Margin rose 500.0% to 48.13% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 69.99% through Dec 2025, up 662.0% year-over-year, with the annual reading at 69.99% for FY2025, 662.0% up from the prior year.
  • FCF Margin was 48.13% for Q4 2025 at Ultragenyx Pharmaceutical, up from 59.69% in the prior quarter.
  • Over five years, FCF Margin peaked at 19.54% in Q4 2021 and troughed at 178.2% in Q1 2024.
  • The 5-year median for FCF Margin is 91.62% (2021), against an average of 98.07%.
  • The largest YoY upside for FCF Margin was 12405bps in 2021 against a maximum downside of -23316bps in 2021.
  • A 5-year view of FCF Margin shows it stood at 19.54% in 2021, then crashed by -335bps to 85.02% in 2022, then rose by 21bps to 67.19% in 2023, then rose by 21bps to 53.13% in 2024, then grew by 9bps to 48.13% in 2025.
  • Per Business Quant, the three most recent readings for RARE's FCF Margin are 48.13% (Q4 2025), 59.69% (Q3 2025), and 64.85% (Q2 2025).